Production (Stage)
Universal Ibogaine Inc.
IBO.V
TSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.53% | -16.35% | 25.07% | 123.76% | 285.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.53% | -16.35% | 25.07% | 123.76% | 285.05% |
| Cost of Revenue | -1.23% | 5.70% | 28.77% | 66.19% | 86.75% |
| Gross Profit | -48.24% | -70.85% | 9.29% | 2,044.02% | 328.37% |
| SG&A Expenses | -51.15% | -26.40% | -34.74% | -41.33% | -53.30% |
| Depreciation & Amortization | 0.73% | 4.30% | 7.48% | 14.55% | 14.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.75% | -2.28% | 1.26% | 3.71% | -16.44% |
| Operating Income | 15.38% | -37.02% | 26.91% | 56.55% | 74.30% |
| Income Before Tax | 7.42% | -88.71% | -23.51% | 15.38% | 75.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.42% | -88.71% | -23.51% | 15.38% | 75.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.42% | -88.71% | -23.51% | 15.38% | 75.03% |
| EBIT | 15.38% | -37.02% | 26.91% | 56.55% | 74.30% |
| EBITDA | 26.68% | -59.71% | 36.67% | 68.54% | 83.34% |
| EPS Basic | 24.00% | -23.40% | 13.04% | 36.17% | 79.42% |
| Normalized Basic EPS | 36.84% | 17.39% | 47.37% | 62.96% | 77.38% |
| EPS Diluted | 8.00% | -40.43% | 1.45% | 27.66% | 81.41% |
| Normalized Diluted EPS | 36.84% | 17.39% | 47.37% | 62.96% | 77.38% |
| Average Basic Shares Outstanding | 38.29% | 51.91% | 36.73% | 21.65% | 12.47% |
| Average Diluted Shares Outstanding | 38.29% | 51.91% | 36.73% | 21.65% | 12.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |